Senores Pharma targets ₹3,000 crore revenue in 3-5 years, expands India and US capacity

Swapnil Shah, Managing Director of Senores Pharmaceuticals, said he expects the company to deliver 30-40% revenue growth in FY27 and around 60% profit growth.